Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BCR-ABL-IN-3 is a highly effective and irreversibly binding inhibitor of Bcr-Abl, displaying a remarkable potency with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151. This compound exhibits significant anti-cancer activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 970.00 |
Description | BCR-ABL-IN-3 is a highly effective and irreversibly binding inhibitor of Bcr-Abl, displaying a remarkable potency with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151. This compound exhibits significant anti-cancer activity. |
Targets&IC50 | BCR-ABL (T3151, Ba/F3 cells):≤100 nM (IC50) |
In vivo | BCR-ABL-IN-3, also known as compound 7, administered at a dose of 15 mg/kg twice daily for 19 days, demonstrated significant antitumor effects in 7-8 week-old female NOD/SCID mice, each weighing 21.8 g and implanted with Ba/F 3 Bcr-Abl T3151 cells[1]. Additionally, in 7-8 week-old male Sprague Dawley rats weighing 210 g, BCR-ABL-IN-3 displayed pharmacokinetic properties with a maximum concentration (C max) of 5485 ng/mL and an area under the curve (AUC) of 5450 h·ng/mL, when administered intravenously (IV) at a dose of 2 mg/kg or orally (PO) at 20 mg/kg[1]. |
Molecular Weight | 466.89 |
Formula | C20H17ClF2N4O3S |
CAS No. | 2240191-12-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BCR-ABL-IN-3 2240191-12-0 BCRABLIN3 BCR ABL IN 3 inhibitor inhibit